Munish Shah, Ph.D.

HCP and Scientific strategy of Pancreatic Cancer of Lynparza • Development and implementation of data driven strategy to expand customer reach, increasing compliance treatment rates • Enhanced marketing strategy, marketing tools, and promotional plans in full alignment with alliance partners cross functionally increasing customer engagement exceeding revenue targets for pancreatic cancer

Brand strategy lead for KEYTRUDA® + LENVIMA® in alliance with Eisai Co., Ltd. • Core cross functional team member of the launch of the first non-chemo option for endometrial cancer (KEYTRUDA® and LENVIMA®), triple negative breast cancer (KEYTRUDA®), and cervical cancer (KEYTRUDA®) surpassing market share targets for each indication • Co-led brand planning, positioning, and messaging workshops as well as leading developing of global promotion content • Spearheaded creation of KEYTRUDA® + LENVIMA® brand campaign globally • Developed and implemented a new operational governance resulting in promotion materials delivered faster to markets worldwide

• Boehringer Ingelheim: GILOTRIF®, landscape treatment development for Non-small cell lung cancer [NSCLC] • Eisai Co., Ltd: Management of MSL training and curriculum for better support of scientific leaders • Integra Connect, LLC: Led broad market research to generate insights of Optune, therapy for Glioblastoma Multiforme, to expand customer reach for those with less experience • Integra Connect, LLC: Coordination of advisory boards with key scientific leaders to align on clinical recommendations in urology • Johnson & Johnson: Focal point of cross functional team between IT project managers to incorporate technology in healthcare products with aim to solve for barriers cross divisionally [medical, legal, regulatory, compliance, etc.], reduced time to market by 6 months

Supported development of a portable ultrasound scanner for the detection of hairline fracture for application in sports medicine. • Managed vendor collaboration for development and clinical assessment of the prototype. • Performed competitive intelligence for prototype design, to assess similar products that had been published, patented, and commercialized to ensure prototype remained unique. • Consulted industry experts and vendors to identify potential target markets and devised market launch strategies

o Endorsed by National Institutes of Health, National Science Foundation, and the Department of Defense. o Developed novel medical device then assessed through 501(k) ISO 10993 protocols, and secured full patent (No. 15/451,039). o Analyzed treatment landscape through primary market research in 1:1s with customers and payers to assess potential for commercialization